A B ST R A CT A deficiency of adenine phosphoribosyltransferase (A-PRTase) is described in four members in three generations of one family. A-PRTase is coded by an autosome and the mutants described in this report are heterozygotes for this enzyme defect. The level of enzyme activity in these heterozygotes was inappropriately low, ranging from 21 to 37% of normal rather than the expected 50%o of normal. Examination of various physical and chemical properties of the A-PRTase obtained from the mutant heterozygotes failed to reveal differences from the normal enzyme. These patients have no discernable abnormality in uric acid production despite the finding that patients with a deficiency of a closely related enzyme, hypoxanthine-guanine phosphoribosyltransferase, invariably produce excessive quantities of uric acid. A relationship of the A-PRTase deficiency to the disturbance in lipoprotein metabolism observed in the propositus has not been firmly established. Possible manifestations of the homozygous form of this enzyme deficiency will require identification of such individuals in the future.
INTRODUCTION
A partial deficiency of an enzyme of purine metabolism, hypoxanthine-guanine phosphoribosyltransferase (HG-PRTase) ( Fig. 1 ), has recently been described in five patients with gout who produce excessive quantities of uric acid (1) . Subjects with a complete deficiency of this enzyme also produce uric acid in excess but in addition have a bizarre neurological and behavioral syndrome characterized by self-mutilation, choreoathetosis, spasticity, and mental deficiency (2) . These findings have suggested that the enzyme HG-PRTase is somehow concerned with the normal regulation of purine biosynthesis in man. Genetic data based on biochemical (3) as well as clinical studies (4) (5) (6) (7) have established that the gene for this enzyme is located on the X-chromosome.
In the present study a previously undescribed deficiency of a closely related enzyme, adenine phosphoribosyltransferase (A-PRTase) ( Fig. 1) , is reported in four members in three generations of one family. Despite apparently close functional similarity of this enzyme to HG-PRTase, its partial deficiency in these subjects is not associated with excessive uric acid excretion. The propositus, however, does have Type II hyperbetalipoproteinemia (8) . From the limited genetic data available in this kindred, the gene for A-PRTase appears to be located on an autosome rather than being X-linked and affected individuals may be heterozygous for the defect, even were determined by methods previously described. The methodology of lipoprotein quantification as well as age and sex-corrected normal limits for these values has been described elsewhere (8) . The ,--. (8) . In each of these subjects, the activity of this enzyme was normal (Table II) .
None of the affected members of the "H" family were hyperuricemic. The propositus excreted 514 mg of uric acid in his daily urine after 4 days of dietary purine restriction (normal < 600 mg/ day). Serum urate at that time was 5.2 mg/100 ml.
The red cell antigenic phenotypes obtained on each member of the "H" family are illustrated in Table III . The data obtained on each subject are compatible with the pedigree proposed in Fig. 2 . The small number of affected individuals prevents an accurate estimate of the linkage of this enzyme with any of these blood groups.
DISCUSSION
In the present study a previously unreported deficiency of an enzyme of purine metabolism, adenine phosphoribosyltransferase (A-PRTase), has been described. The reduced A-PRTase activity in the propositus, E. H., has been constant with repeated assay over a period of 8 is heterozygous for the enzyme defect despite normal erythrocyte A-PRTase activity if it is assumed on the basis of the Lyon hypothesis that there was early inactivation of the abnormal X-chromosome in the hematopoietic system in this individual. However, recent studies in other families of a thermostable A-PRTase isoenzyme which has normal enzyme activity revealed that male to male transmission of this allele did occur,2 providing strong evidence that A-PRTase is not X-linked and therefore must be coded for by autosomal DNA. The proposed mode of inheritance is also based on the assumption of full penetrance, the absence of a "neutralizing" or "suppressor" factor in the apparently unaffected daughter, and the proposed parenthood which is in agreement with the erythrocyte antigenic phenotypes.
The failure to detect evidence of a structural abnormality in the A-PRTase obtained from the propositus is compatible with the suggestion that he is a heterozygote and that the enzyme present is the product of only the normal allele. The normal allele would be expected to code for a normal A-PRTase, whereas the mutant allele might code for a protein with no enzyme activity by our assay. It must be emphasized, however, that many structural gene mutations are possible which might affect enzyme activity and not alter the properties which we have examined and that indisputable evidence for a structurally normal A-PRTase in this kindred would require knowledge of its full amino acid sequence.
In most autosomal disorders in which adequate studies of enzyme activity in heterozygotes have been conducted, the enzyme activity in question is absent in the mutant homozygotes (9) . This unexpected finding in the heterozygotes for orotic aciduria has been attributed to the presence of an abnormal regulator gene product produced at the mutant locus (12) . Preliminary data reported by Krooth, using cultured fibroblasts derived from a mutant homozygote with this disorder, led him also to conclude that the mutation may be at a regulator site, rather than on a structural gene (13, 14) .
The A-PRTase activities observed in the four subjects heterozygous for this enzyme defect ranged from 21 to 37%o of normal. Because these values are inappropriately low and similar in range to the enzyme values reported in the heterozygotes for orotic aciduria, a regulator gene mutation could be proposed by analogy with the latter case. The inappropriately low enzyme activity, however, could also result from a structural gene mutation and this finding in itself does not necessarily require that a regulator mutation be postulated. One possible model for such a reduction in activity due to a structural gene mutation would require the enzyme to be a dimer formed by random aggregation of identical subunits from each allele. If this protein had enzymatic activity only when it existed as a dimer composed of two normal subunits, then a structural gene mutation involving one allele in the heterozygote would lead to a reduction in enzyme activity to values approximately 25%o of normal, as is observed in both A-PRTase deficiency and orotic aciduria. There is, in fact, some evidence which suggests a subunit composition for A-PRTase.3 It is apparent that what seems by our present techniques to be a structurally normal A-PRTase in the mutant heterozygotes is compatible not only with a mutation on a structural gene as discussed earlier, but also with an alteration at a regulator site. In conclusion, it is not possible at this time to determine whether the mutation in the "H" family involves a site on a structural or on a regulator gene.
In addition to the similarities noted in the heterozygotes deficient for these enzymes, orotate phosphoribosyltransferase and A-PRTase also have quite similar enzymatic functions since they catalyze the transfer of the ribose-5-phosphate moiety of 5'-phosphoribosyl-1-pyrophosphate to a pyrimidine and purine base, respectively, to form the appropriate 5'-mononucleotides. The possibility that the four subjects in this report were actually heterozygotes for orotic aciduria and that the reduced A-PRTase activity observed reflected either a deficiency of yet a third enzyme in orotic aciduria or the reduced orotate phosphoribosyltransferase activity itself, has been excluded, since orotate phosphoribosyltransferase activty was normal in the propositus.
The subjects in this report had no detectable abnormality of purine metabolism despite the finding that the deficiency of a closely related enzyme, HG-PRTase, is always associated with excessive purine synthesis.
The relationship of the A-PRTase deficiency and the hyperbetalipoproteinemia observed in the propositus is not known. This abnormal lipoprotein pattern is often familial, being inherited as an autosomal dominant (8) . The common causes of acquired hyperbetalipoproteinemia including exaggerated dietary intake of cholesterol, hypothyroidism, nephrosis, myeloma, macroglobulinemia, and obstructive liver disease were excluded in this patient. The failure to find evidence of hyperbetalipoproteinemia in the remainder of the family studied was somewhat surprising, but far from inconceivable on genetic grounds. However, since no other family members had hyperbetalipoproteinemia, evidence of complete genetic segregation of these two biochemical disorders could not be obtained in this kinship. Evaluation of the father of the propositus could have provided definitive evidence of such genetic segregation, but he died in an accident in middle age without a clinical history of cardiovascular disease.
There are many apparent interrelationships between purine and lipoprotein metabolism which are unanswered. An elevated serum urate, the ultimate end product of purine metabolism in man, frequently occurs in patients with hypertriglyceridemia (Type III, IV, and V hyperlipoproteinemia) (15, 16, 8) although this association is not usually noted in patients such as the propositus, with hyperbetalipoproteinemia (Type II) (17, 8) .
Beta lipoprotein release from the liver in rats can be strongly inhibited by the administration of orotic acid, an effect which is completely reversed by exogenous adenine, suggesting that purines and pyrimidines may be involved in the regulation of betalipoprotein metabolism (18) . Patients with familial Type II hyperlipoproteinemia have an increased quantity of a lipoprotein which is structurally normal (8) , suggesting that the mutation responsible for this abnormality acts by producing a defect in a normal control mechanism. High normal beta lipoprotein levels in the mother and normal concentrations of beta lipoprotein in the two young daughters of the propositus, who also had reduced A-PRTase activity, suggest that the association of these two metabolic disorders may have been fortuitous in the propositus. It is possible that the two girls with the enzyme defect will ultimately manifest this disorder of lipoprotein metabolism, but the failure of the mother of the propositus to demonstrate this lipoprotein abnormality argues strongly against a causal relationship of these two disorders. Certainly the apparent high incidence of hyperbetalipoproteinemia in the American population would not mitigate against a chance association. The possibility still remains that hyperbetalipoproteinemia is expressed in association with A-PRTase deficiency only in the male. A-PRTase activity, however, was normal in six unrelated adult patients with familial Type II hyperlipoproteinemia, suggesting that the deficiency of this enzyme, if causally related at all, is not the basic defect in most patients with this disorder. Further studies are being conducted in the propositus in an attempt to delineate this issue.
No attempt has been made to estimate frequency of this mutation but the propositus was discovered in the course of assay of blood samples from about 150 subjects. The possible manifestations of this enzyme defect in the homozygote are difficult to predict. However, it would seem unlikely to us at this time that this would be a lethal mutation since the product of this reaction, adenylic acid, can be formed in most tissues by alternative biochemical pathways. Furthermore, normal growth of mutant mammalian cells (AMK) completely deficient in this enzyme, has been reported (19) . On the other hand, mature human erythrocytes which lack a de novo pathway for synthesis of purine ribonucleotides might be adversely affected by a very low A-PRTase activity, particularly since the alternative pathways for the synthesis of adenylic acid from adenosine and inosinic acid are lacking in these cells (20) . The possibility of finding a more severe deficiency of A-PRTase among patients with unexplained congenital hemolytic anemia remains to be explored.
